NASDAQ:VIRX
Viracta Therapeutics, Inc. Stock News
$0.735
+0.0079 (+1.09%)
At Close: May 24, 2024
Viracta Therapeutics to Host R&D Day Highlighting Nana-val in Epstein-Barr Virus (EBV)-Associated Cancers
07:00am, Wednesday, 04'th Oct 2023
Preliminary clinical data from patients with relapsed/refractory EBV + peripheral T-cell lymphoma in the pivotal NAVAL-1 trial demonstrated overall and complete response rates of 40%; follow-up from t
Viracta Therapeutics to Host R&D Day on October 4, 2023
09:00am, Tuesday, 05'th Sep 2023
SAN DIEGO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers
Viracta Therapeutics Announces New Employment Inducement Grant
04:05pm, Friday, 18'th Aug 2023
SAN DIEGO, Aug. 18, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers
Viracta Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
08:00am, Monday, 14'th Aug 2023
Achieved efficacy threshold to advance Epstein-Barr virus-positive (EBV + ) peripheral T-cell lymphoma into Stage 2 becoming the leading indication in pivotal NAVAL-1 study of Nana-val
Results from Phase 1b/2 trial showed complete responses achieved and ongoing durable responses observed out to approximately 36 months across multiple EBV + lymphoma subtypes, including some of the mo
Viracta Therapeutics to Present at the Jefferies Healthcare Conference
04:15pm, Wednesday, 31'st May 2023
SAN DIEGO, May 31, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact pati
Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
04:05pm, Thursday, 11'th May 2023
SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact pati
Viracta Therapeutics to Present at the Stifel 2023 Targeted Oncology Days
04:30pm, Wednesday, 19'th Apr 2023
SAN DIEGO, April 19, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact pa
Viracta Therapeutics to Present at the 33rd Annual Oppenheimer Healthcare Conference
04:05pm, Wednesday, 08'th Mar 2023
SAN DIEGO, March 08, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact pa
Viracta Therapeutics to Present at the 2023 SVB Securities Global Biopharma Conference
04:05pm, Tuesday, 07'th Feb 2023
SAN DIEGO, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact pat
Viracta (VIRX) Up on Orphan Drug Tag for Peripheral Lymphoma
02:18pm, Thursday, 08'th Sep 2022
Viracta (VIRX) receives Orphan Drug designation from the European Commission for its lead candidate Nana-val for treating peripheral T-cell lymphoma. Stock up.
Here's Why Viracta Therapeutics (VIRX) is Up So Far This Year
09:19am, Monday, 11'th Jul 2022
Viracta Therapeutics' (VIRX) Nana-val is being evaluated in multiple clinical studies in various subtypes of EBV-associated cancers.
4 Small Stocks to Bet on in an Upbeat Drugs Industry
10:54am, Wednesday, 06'th Jul 2022
It is expected that innovation will continue to drive growth in the Medical-Drugs industry in 2022. KDNY, ASRT, VIRX, SLNO may prove to be good additions to one's portfolio.
Viracta Therapeutics to Present at the Jefferies Healthcare Conference
04:15pm, Wednesday, 01'st Jun 2022
SAN DIEGO , June 1, 2022 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that company management is sc
Viracta Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference
10:13am, Thursday, 07'th Apr 2022
SAN DIEGO , April 7, 2022 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that company leadership is